Abstract 62P
Background
Cervical intraepithelial neoplasia (CIN) is regarded as a precancerous condition of the cervix. The tumor microenvironment contains a large number of immune cells, in particular, tumor-associated neutrophils (Nph), as well as pro-inflammatory cytokines, including IL6, which causes chronic inflammation and immunosuppression. The role of IL6 in the onset and progression of CIN has been shown (Chen J, Wang L, 2022). Regulation of cytokine expression occurs at the transcriptional level, in the promoter region of the gene. For IL6, a single nucleotide polymorphism (SNP) with a substitution at position -174G→C has been described that is associated with the risk of breast cancer. IL6 polymorphism (rs2069837) is significantly associated with an increased risk of cervical cancer (Das AP, et al, 2022). However, there is no data on the involvement of SNP IL6 C-174G (rs1800795) in the occurrence and development of CIN. The aim of the study was to evaluate the role of IL6 (C-174G) polymorphism in the development of CIN.
Methods
The study included 60 patients diagnosed with high-grade squamous intraepithelial lesions (CIN II, CIN III and cancer in situ) and 30 somatically healthy women (control). The study was conducted in accordance with the requirements of the ethics commission of UlSU. The level of IL6 was determined in Nph lysate by ELISA method (Vector-Best, Russia). The presence of SNP IL6 C-174G was assessed by polymerase chain reaction with restriction enzyme analysis using RsaI endonuclease (SibEnzyme, Russia). Electrophoresis was carried out in 1.5% agarose gel. Statistical processing was carried out using Statistica 13.
Results
It was found that the -174G* allele is more common in the group with lesions of the cervix (75.7%) than in the control (53.3%). The risk of developing CIN increased with an increase in the level of IL6 in Nph with CIN (9.69 (6.89-10.85) vs 1.33 (0.78-2.25), p=0.015) and the presence of the -174G allele * (OR=0.411, 95% CI 0.220-0.768, p=0.005) (χ2=23.4, p=0.001).Simultaneous assessment of the level of IL6 in Nph and SNP IL6 C-174G allows predicting the development of CIN with sensitivity (0.769) and specificity (0.897).
Conclusions
The presence of IL6 polymorphism (C-174G) and an elevated level of IL6 in Nph indicate the possibility of CIN.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
41P - HLA genotypes modify the age-related penetrance of BRCA1 pathogenic variants in breast cancer patients
Presenter: Ekaterina Kuligina
Session: Cocktail & Poster Display session
Resources:
Abstract
42P - Investigating the influence of extrachromosomal DNA in the progression of non-small cell lung cancer through the TRACERx and PEACE studies
Presenter: Jeanette Kittel
Session: Cocktail & Poster Display session
Resources:
Abstract
43P - MDM2 alterations in primary brain tumors: A potential niche for targeted therapy
Presenter: Diego Gomez Puerto
Session: Cocktail & Poster Display session
Resources:
Abstract
44P - Exploring miR-205 and miR-296 as salivary biomarkers and potential therapeutic targets in oral cancer
Presenter: Thaís Moré Milan
Session: Cocktail & Poster Display session
Resources:
Abstract
45P - Integrative analysis of TCGA DNA methylation, RNA-sequencing, and variant dataset using machine learning in predicting endometrial cancer recurrence
Presenter: Jinhwa Hong
Session: Cocktail & Poster Display session
Resources:
Abstract
46P - The role of microRNA-1246 in early detection of breast cancer: Findings from a systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
47P - Differential expression of discriminative markers in matched invasion fronts and tumour buds in CRC
Presenter: Laura Grech
Session: Cocktail & Poster Display session
Resources:
Abstract
48P - Transcriptome profiling highlights distinct gene signatures in HER2 high (HER2 3+) and HER 2 low (Her2 1+/2+) breast cancers
Presenter: Tamanna Thakur
Session: Cocktail & Poster Display session
Resources:
Abstract
49P - MiR-155 promotes breast cancer progression by upregulating cancer stemness
Presenter: Jeonghee Han
Session: Cocktail & Poster Display session
Resources:
Abstract
50P - Clinical impact of actionable molecular variants disclosed in late-stage cancer patients by tumor whole-exome sequencing in a prospective single-institution study
Presenter: Christophe Mapendano
Session: Cocktail & Poster Display session
Resources:
Abstract